KYMR Kymera Therapeutics, Inc.
Healthcare$79.66+0.00%OpenMarket Cap: $6.55B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
5.00
P/S
126.09
EV/EBITDA
-21.00
DCF Value
$0.17
FCF Yield
-3.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-697.8%
Net Margin
-612.2%
ROE
-25.0%
ROA
-18.9%
ROIC
-22.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $34.4M | 100.0% | $-84.2M | $-69.2M | $— | — |
| Q4 null | $2.9M | 2763.6% | $-97.9M | $-87.0M | $— | — |
| FY null | $39.2M | 100.0% | $-349.4M | $-311.4M | $— | — |
| Q3 null | $2.8M | -2580.7% | $-92.5M | $-82.2M | $— | — |
| Q2 null | $11.5M | 81.8% | $-84.6M | $-76.6M | $— | — |
| Q1 null | $22.1M | 100.0% | $-74.4M | $-65.6M | $— | — |
| Q4 null | $7.4M | 100.0% | $-80.8M | $-70.8M | $— | — |
| FY null | $47.1M | 100.0% | $-261.6M | $-223.9M | $— | — |
| Q3 null | $3.7M | 100.0% | $-72.1M | $-62.5M | $— | — |
| Q2 null | $25.6M | 100.0% | $-50.9M | $-42.1M | $— | — |
| Q1 null | $10.3M | 100.0% | $-57.8M | $-48.6M | $— | — |
| Q4 2023 | $47.9M | 100.0% | $-19.3M | $-14.4M | $-0.25 | — |